U.S. Markets close in 4 hrs 11 mins

Today's Research Reports on Hemostemix, Fennec Pharmaceuticals, Sernova and Covalon Technologies

NEW YORK, NY / ACCESSWIRE / January 10, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.com and get exclusive access to our numerous research reports and market updates.

The Market Edge Initiates Coverage on:

Hemostemix Inc.
https://marketedgereport.com/report/HEM.V/

Fennec Pharmaceuticals Inc.
https://marketedgereport.com/report/FRX.TO/

Sernova Corp.
https://marketedgereport.com/report/SVA.V/

Covalon Technologies Ltd.
https://marketedgereport.com/report/COV.V/

Hemostemix's stock had no change Wednesday, to close the day at $0.10. The stock recorded a trading volume of 61,899 shares, which was below its three months average volume of 145,720 shares. In the last year, Hemostemix's shares have traded in a range of 0.05 - 0.14. The share price has gained 100% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.10 is greater than its 200-day moving average of $0.09. Shares of Hemostemix have gained approximately 81.82 percent in the last year.

Access The Market Edge's Hemostemix Inc. Research Report:
https://marketedgereport.com/report/HEM.V/

On Wednesday, shares of Fennec Pharmaceuticals recorded a trading volume of 500 shares, which was below the three months average volume of 1,971 shares. The stock ended the day 3.21% lower at $9.34. The share price has fallen 50.48% from its 52 week high with a 52 week trading range of 7.22 - 18.86. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $8.61 is lower than its 200-day moving average of $10.71. Shares of Fennec Pharmaceuticals have fallen approximately 21.25 percent in the last year.

Access The Market Edge's Fennec Pharmaceuticals Inc. Research Report:
https://marketedgereport.com/report/FRX.TO/

Sernova's stock moved 2.56% lower Wednesday, to close the day at $0.19. The stock recorded a trading volume of 190,500 shares, which was above its three months average volume of 150,284 shares. In the last year, Sernova's shares have traded in a range of 0.17 - 0.47. The share price has gained 11.76% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.20 is lower than its 200-day moving average of $0.21. Shares of Sernova have fallen approximately 56.82 percent in the last year.

Access The Market Edge's Sernova Corp. Research Report:
https://marketedgereport.com/report/SVA.V/

On Wednesday, shares of Covalon Technologies recorded a trading volume of 24,240 shares, which was above the three months average volume of 15,419 shares. The stock ended the day 8.75% higher at $4.35. The share price has fallen 53.97% from its 52 week high with a 52 week trading range of 3.22 - 9.45. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.98 is lower than its 200-day moving average of $7.05. Shares of the company are trading at a Price to Earnings ratio of 62.14. Shares of Covalon Technologies have fallen approximately 16.51 percent in the last year.

Access The Market Edge's Covalon Technologies Ltd. Research Report:
https://marketedgereport.com/report/COV.V/

Our Actionable Research on Hemostemix Inc. (TSXV : HEM.V ), Fennec Pharmaceuticals Inc. (TSX : FRX.TO ), Sernova Corp. (TSXV : SVA.V ) and Covalon Technologies Ltd. (TSXV : COV.V ) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: MarketEdgeReport